Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstein, Bayarmagnai, Muresan, Bogdan, Solano, Sara, de Macedo, Antonio Vaz, Lee, YoonJung, Su, Yu-Chen, Ahn, Yeseul, Henriquez, Gabriela, Camargo, Cristina, Kim, Gwang-Jin, Carpenter, David O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401376/
https://www.ncbi.nlm.nih.gov/pubmed/36033121
http://dx.doi.org/10.24926/iip.v12i4.4345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401376/
https://www.ncbi.nlm.nih.gov/pubmed/36033121
http://dx.doi.org/10.24926/iip.v12i4.4345

Ejemplares similares